Patents by Inventor Ian David Wall

Ian David Wall has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS
    Publication number: 20180282301
    Abstract: The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy
    Type: Application
    Filed: September 20, 2016
    Publication date: October 4, 2018
    Inventors: Stephen John ATKINSON, Emmanuel Hubert, Lee Andrew HARRISON, Thomas HAYHOW, David HOUSE, Matthew J. LINDON, Alexander G. PRESTON, Jonathan Thomas SEAL, IAN David WALL, Robert J. WATSON, James Michael WOOLVEN
  • PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS
    Publication number: 20180258044
    Abstract: The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy
    Type: Application
    Filed: August 31, 2016
    Publication date: September 13, 2018
    Inventors: Stephen John ATKINSON, Helen Elizabeth AYLOTT, Anthony William James COOPER, Emmanuel Hubert DEMONT, Lee Andrew HARRISON, Thomas George Christopher HAYHOW, Matthew J. LINDON, Alexander G. PRESTON, Jonathan Thomas SEAL, Ian David WALL, Robert J. WATSON, James Michael WOOLVEN
  • 5,6,7,8-tetrahydroimidazo[1,2-A]pyrazine derivatives as P2X7 modulators
    Patent number: 8513248
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein A is hydrogen, C1-4alkyl, C3-6cycloalkyl, C1-3alkoxy, C1-3alkoxy C1-4alkyl, C1-2fluoroalkyl, halogen, NR6R7, optionally substituted heteroaryl (Het), or optionally substituted phenyl, and R1, R2, R3, R4, R5, R6 and R7 are as defined in the description. The compounds or salts are thought to modulate P2X7 receptor function and to be capable of antagonizing the effects of ATP at the P2X7 receptor. The invention also provides the use of the compound or salt in the treatment or prophylaxis of, for example, inflammatory pain, neuropathic pain, visceral pain, rheumatoid arthritis or osteoarthritis or neurodegenerative disorders.
    Type: Grant
    Filed: April 28, 2010
    Date of Patent: August 20, 2013
    Assignee: Glaxo Group Limited
    Inventors: David Kenneth Dean, Jorge Munoz-Muriedas, Mairi Sime, Jon Graham Anthony Steadman, Rachel Elizabeth Anne Thewlis, Giancarlo Trani, Ian David Wall, Daryl Simon Walter
  • Oxadiazole derivatives active on sphingosine-1-phosphate (S1P)
    Patent number: 8222245
    Abstract: The present invention relates to novel oxadiazole derivatives having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.
    Type: Grant
    Filed: December 19, 2008
    Date of Patent: July 17, 2012
    Assignee: Glaxo Group Limited
    Inventors: Emmanuel Hubert Demont, Jag Paul Heer, John Skidmore, Ian David Wall, Jason Witherington, Thomas Daniel Heightman, David Nigel Hurst, Christopher Norbert Johnson
  • 5,6,7,8-TETRAHYDROIMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS P2X7 MODULATORS
    Publication number: 20120172366
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein A is hydrogen, C1-4alkyl, C3-6cycloalkyl, C1-3alkoxy, C1-3alkoxy C1-4alkyl, C1-2fluoroalkyl, halogen, NR6R7, optionally substituted heteroaryl, or optionally substituted phenyl, and R1, R2, R3, R4, R5, R6 and R7 are as defined in the description. The compounds or salts are thought to modulate P2X7 receptor function and to be capable of antagonizing the effects of ATP at the P2X7 receptor. The invention also provides the use of the compound or salt in the treatment or prophylaxis of, for example, inflammatory pain, neuropathic pain, visceral pain, rheumatoid arthritis or osteoarthritis or neurodegenerative disorders.
    Type: Application
    Filed: April 28, 2010
    Publication date: July 5, 2012
    Inventors: David Kenneth Dean, Jorge Munoz-Muriedas, Mairi Sime, Jon Graham Anthony Steadman, Rachel Elizabeth Anne Thewlis, Giancarlo Trani, Ian David Wall, Daryl Simon Walter
  • 1, 2, 4 -OXADIAZOLE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
    Publication number: 20100273770
    Abstract: The present invention relates to novel oxadiazole derivatives having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.
    Type: Application
    Filed: December 19, 2008
    Publication date: October 28, 2010
    Inventors: Jag Paul Heer, Thomas Daniel Heightman, David Nigel Hurst, Christopher Norbert Johnson, John Skidmore, Ian David Wall
  • OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (SIP)
    Publication number: 20100273771
    Abstract: The present invention relates to novel oxadiazole derivatives having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.
    Type: Application
    Filed: December 19, 2008
    Publication date: October 28, 2010
    Inventors: Emmanuel Hubert Demont, Jag Paul Heer, John Skidmore, Ian David Wall, Jason Witherington, Thomas Daniel Heightman, David Nigel Hurst, Christopher Norbert Johnson
  • COMPOUNDS
    Publication number: 20100174065
    Abstract: The present invention relates to novel oxadiazole derivatives having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.
    Type: Application
    Filed: January 28, 2009
    Publication date: July 8, 2010
    Applicant: GLAXO GROUP LIMITED
    Inventors: Jag Paul HEER, Thomas Daniel HEIGHTMAN, David Nigel HURST, Christopher Norbert JOHNSON, John SKIDMORE, Ian David WALL
  • 2-(Phenylamino)-Pyrimidin-5-Amides As Cannabinoid 2 Receptors Modulators for the Treatment of Immune or Inflammatory Disorders
    Publication number: 20090264452
    Abstract: The present invention relates to novel pyrimidine derivatives such as compounds of the formula (I): and the use of such compounds or pharmaceutical compositions thereof in the treatment of diseases, particularly pain, which are mediated by the activity of the cannabinoid 2 receptor.
    Type: Application
    Filed: February 1, 2005
    Publication date: October 22, 2009
    Inventors: Andrew John Eatherton, Gerard Martin Paul Giblin, William Leonard Mitchell, Alan Naylor, Derek Anthony Rawlings, Ian David Wall
  • Pyridine Derivatives as Connabinoid Receptor Modulators
    Publication number: 20080280952
    Abstract: The present invention relates to novel pyridine derivatives such as compounds of the formula (I): and the use of such compounds or pharmaceutical compositions thereof in the treatment of diseases, particularly pain, which are mediated by the activity of the cannabinoid 2 receptor.
    Type: Application
    Filed: February 1, 2005
    Publication date: November 13, 2008
    Inventors: Gerard Martin Paul Giblin, Karamjit Singh Jandu, William Leonard Mitchell, Ian David Wall